#theranostics
Discover 5 curated intelligence briefings related to this specific topic.
The Mitochondrial Ceiling: Why Cellular Energy is the Hard Limit of Human Longevity
A strategic analysis of why mitochondrial decay, not genomic instability, represents the true bottleneck for human lifespan extension, and why our current obsession with the genetic blueprint is missing the power source.
The Death of the Average: Why Biological Age is Dismantling Preventative Medicine
For decades, medicine relied on population averages to predict health outcomes. Now, the rise of biological age tracking—driven by epigenetic clocks and blood biomarkers—is rendering the birth certificate obsolete and forcing a radical pivot toward personalized longevity.
The Biological Border: How Molecular Longevity is Redefining the Class Divide
As age-reversal gene therapies enter human trials, the quest for eternal youth is shifting from a public health goal to a luxury commodity, threatening to create a permanent biological caste system.
The Atomic Scalpel: Radioligand Therapy's Pivot to the Front Lines
Radioligand therapy is shedding its reputation as a last-resort treatment. From the shift toward alpha-emitters to the integration of theranostics, we analyze how the precision strike is moving up the line of care across global health systems.
The Atomic Scalpel: Why Radioligand Therapy is the Silent Pivot in Oncology
While the world focused on CAR-T and mRNA, a quieter revolution in radiopharmaceuticals began. Radioligand therapy is not just a new drug class; it is a fundamental shift in the logistics of survival, turning the cancer cell's own receptors into the trigger for its destruction.